Đang chuẩn bị liên kết để tải về tài liệu:
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: A systematic review and meta-analysis of published randomized controlled trials
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Nowadays, canagliflozin monotherapy, or in combination with other oral hypoglycemic agents (OHAs), is often administered in patients who are treated for type 2 diabetes mellitus (T2DM). | Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: A systematic review and meta-analysis of published randomized controlled trials